Oncolytics Biotech Inc T.ONC

Hi all,

[canadafan]

Hello nitable, I sent you a message, could you answer please.
regards
 cf

[Noteable]

Perhaps it has something to do with Roche having stated in their last quarterly report that they were shifting R&D dollars into M&A activities. 

[Noteable]

That prioritization into M&A dollars could be coming from Roche's TIGIT R&D  program. 

[canadafan]

I think many would be pleased to see Onc be bought out by a Roche. They certainly know Onc/ Palareorep clinical potential. They have been working alongside , with ONC for a very long time. Again, endorsement from CGAR to $5million grant.FDA favourable directions, including fast track designation for MBc & panc cancer. With discussions of potential accelerated approval. All "value added

[13X2413]

CF, enjoy your posts. One thing pops out in your latest. Many junior BT's with much less have been bought out. The question is why? Is it because ONC doesn't actually have less than those other juniors?